BlackRock
AURA icon

BlackRock’s Aura Biosciences AURA Stock Holding History

BlackRock’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.4M Buy
4,707,674
+1,121,034
+31% +$8.02M ﹤0.01% 2925
2026
Q1 		$24M Buy
3,586,640
+26,216
+0.7% +$150K ﹤0.01% 2958
2025
Q4 		$19.4M Buy
3,560,424
+154,947
+5% +$920K ﹤0.01% 3122
2025
Q3 		$21M Buy
3,405,477
+302,953
+10% +$1.98M ﹤0.01% 3066
2025
Q2 		$19.4M Sell
3,102,524
-437,424
-12% -$2.56M ﹤0.01% 3049
2025
Q1 		$20.7M Sell
3,539,948
-11,509
-0.3% -$87.1K ﹤0.01% 2917
2024
Q4 		$29.2M Buy
3,551,457
+391,043
+12% +$3.68M ﹤0.01% 2804
2024
Q3 		$28.2M Buy
3,160,414
+155,052
+5% +$1.33M ﹤0.01% 2815
2024
Q2 		$22.7M Buy
3,005,362
+560,521
+23% +$4.11M ﹤0.01% 2905
2024
Q1 		$19.2M Buy
2,444,841
+346,096
+16% +$2.87M ﹤0.01% 3014
2023
Q4 		$18.6M Buy
2,098,745
+234,719
+13% +$1.99M ﹤0.01% 3050
2023
Q3 		$16.7M Sell
1,864,026
-8,106
-0.4% -$87.2K ﹤0.01% 3046
2023
Q2 		$23.1M Buy
1,872,132
+541,032
+41% +$5.78M ﹤0.01% 2940
2023
Q1 		$12.4M Buy
1,331,100
+277,973
+26% +$2.89M ﹤0.01% 3202
2022
Q4 		$11.1M Buy
1,053,127
+39,672
+4% +$505K ﹤0.01% 3351
2022
Q3 		$18.4M Buy
1,013,455
+126,732
+14% +$1.92M ﹤0.01% 3083
2022
Q2 		$12.6M Buy
886,723
+611,696
+222% +$10.1M ﹤0.01% 3385
2022
Q1 		$6.05M Buy
275,027
+36,244
+15% +$690K ﹤0.01% 3859
2021
Q4 		$4.05M Buy
+238,783
New +$4.27M ﹤0.01% 4083

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock's AURA Position: Q2 2026 in Review

BlackRock increased its Aura Biosciences (AURA) stake by 31% in Q2 2026, buying an estimated $8.02M and bringing the position to 4,707,674 shares worth $33.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2925.

BlackRock first reported a position in AURA in Q4 2021 and has held it in 19 quarters since. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • BlackRock held 4,707,674 shares of Aura Biosciences worth $33.4M as of Q2 2026.
  • BlackRock bought 1,121,034 Aura Biosciences shares in Q2 2026, an estimated $8.02M.
  • Aura Biosciences made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2925 holding.
  • BlackRock first reported a position in Aura Biosciences in Q4 2021 and has held it in 19 quarters since.
  • 146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.